Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?

The aim of the study was to assess the occurrence and nature of immune-related endocrine adverse events (irAEs) among patients with non-small-cell lung cancer (NSCLC) treated with nivolumab.<h4>Methods</h4>The study group included 35 patients (15 women, 20 men, 65.8 ± 7.1 years) with NSC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Izabela Chmielewska, Marta Dudzińska, Michał Szczyrek, Joanna Świrska, Kamila Wojas-Krawczyk, Agnieszka Zwolak
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/957a972f916045bdb2d357d2b90ec215
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:957a972f916045bdb2d357d2b90ec215
record_format	dspace
spelling	oai:doaj.org-article:957a972f916045bdb2d357d2b90ec2152021-12-02T20:14:03ZDo endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?1932-620310.1371/journal.pone.0257484https://doaj.org/article/957a972f916045bdb2d357d2b90ec2152021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257484https://doaj.org/toc/1932-6203The aim of the study was to assess the occurrence and nature of immune-related endocrine adverse events (irAEs) among patients with non-small-cell lung cancer (NSCLC) treated with nivolumab.<h4>Methods</h4>The study group included 35 patients (15 women, 20 men, 65.8 ± 7.1 years) with NSCLC in stage IIIB (n = 16, 45.7%) and IV (n = 19,54.3%) who were treated with nivolumab.<h4>Results</h4>Of the studied patients, 34.3% (n = 12) developed endocrine irAEs (irAE group): 22.9% (n = 8) hyperthyroidism and 8.6% (n = 3) hypothyroidism, and in one case, hypophysitis was observed. The median irAEs onset time was 2 months. In the group of patients with thyroid disorders, permanent hypothyroidism eventually developed in 58.3%. The severity of the analyzed irAEs ranged from mild to moderate (Grade 1-2); the case of hypophysitis was estimated as Grade 3. The comparison of progression-free survival time (PFS) between the two groups showed longer PFS in patients in the irAE group (p = 0.021). Patients with irAE were treated significantly longer with nivolumab and they received more doses of nivolumab, however in Cox analysis we did not find patients with irAE to experience progression later than patients without them.<h4>Conclusions</h4>Nivolumab therapy is associated with an increased risk of endocrine adverse effects, particularly thyroid dysfunction. Endocrine adverse effects can be successfully treated pharmacologically and usually do not require discontinuation of immunotherapy. The relationship between a better cancer prognosis in patients who developed endocrine irAE has not been found.Izabela ChmielewskaMarta DudzińskaMichał SzczyrekJoanna ŚwirskaKamila Wojas-KrawczykAgnieszka ZwolakPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257484 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Izabela Chmielewska Marta Dudzińska Michał Szczyrek Joanna Świrska Kamila Wojas-Krawczyk Agnieszka Zwolak Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
description	The aim of the study was to assess the occurrence and nature of immune-related endocrine adverse events (irAEs) among patients with non-small-cell lung cancer (NSCLC) treated with nivolumab.<h4>Methods</h4>The study group included 35 patients (15 women, 20 men, 65.8 ± 7.1 years) with NSCLC in stage IIIB (n = 16, 45.7%) and IV (n = 19,54.3%) who were treated with nivolumab.<h4>Results</h4>Of the studied patients, 34.3% (n = 12) developed endocrine irAEs (irAE group): 22.9% (n = 8) hyperthyroidism and 8.6% (n = 3) hypothyroidism, and in one case, hypophysitis was observed. The median irAEs onset time was 2 months. In the group of patients with thyroid disorders, permanent hypothyroidism eventually developed in 58.3%. The severity of the analyzed irAEs ranged from mild to moderate (Grade 1-2); the case of hypophysitis was estimated as Grade 3. The comparison of progression-free survival time (PFS) between the two groups showed longer PFS in patients in the irAE group (p = 0.021). Patients with irAE were treated significantly longer with nivolumab and they received more doses of nivolumab, however in Cox analysis we did not find patients with irAE to experience progression later than patients without them.<h4>Conclusions</h4>Nivolumab therapy is associated with an increased risk of endocrine adverse effects, particularly thyroid dysfunction. Endocrine adverse effects can be successfully treated pharmacologically and usually do not require discontinuation of immunotherapy. The relationship between a better cancer prognosis in patients who developed endocrine irAE has not been found.
format	article
author	Izabela Chmielewska Marta Dudzińska Michał Szczyrek Joanna Świrska Kamila Wojas-Krawczyk Agnieszka Zwolak
author_facet	Izabela Chmielewska Marta Dudzińska Michał Szczyrek Joanna Świrska Kamila Wojas-Krawczyk Agnieszka Zwolak
author_sort	Izabela Chmielewska
title	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
title_short	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
title_full	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
title_fullStr	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
title_full_unstemmed	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
title_sort	do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/957a972f916045bdb2d357d2b90ec215
work_keys_str_mv	AT izabelachmielewska doendocrineadverseeventspredictlongerprogressionfreesurvivalamongpatientswithnonsmallcelllungcancerreceivingnivolumab AT martadudzinska doendocrineadverseeventspredictlongerprogressionfreesurvivalamongpatientswithnonsmallcelllungcancerreceivingnivolumab AT michałszczyrek doendocrineadverseeventspredictlongerprogressionfreesurvivalamongpatientswithnonsmallcelllungcancerreceivingnivolumab AT joannaswirska doendocrineadverseeventspredictlongerprogressionfreesurvivalamongpatientswithnonsmallcelllungcancerreceivingnivolumab AT kamilawojaskrawczyk doendocrineadverseeventspredictlongerprogressionfreesurvivalamongpatientswithnonsmallcelllungcancerreceivingnivolumab AT agnieszkazwolak doendocrineadverseeventspredictlongerprogressionfreesurvivalamongpatientswithnonsmallcelllungcancerreceivingnivolumab
_version_	1718374720767787008

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?

Ejemplares similares